Digitalizing biopharma: How raw material data can maximize vaccines manufacturing supply chain and practices

Scaling up vaccines fast, while maintaining safety and efficiency, is one of the urgent challenges for biopharma companies fighting against COVID-19. AI, big data and smart systems are being leveraged to help transform the business model of biopharma 4.0, not only in vaccines manufacturing. From incoming good receipts and raw material testing, to process development, manufacturing troubleshooting and predictive analytics targeting consistent and predictable biomanufacturing, data exchange programs with raw material manufacturers can have an immediate impact in the journey of creating a digital vaccines manufacturing process that improves productivity on a large scale, while reducing costs.